Fast Track Immunology Asset Will Debut Amid Execution Risks

Nektar Therapeutics' analyst price target has been revised downward from $101.17 to $93.86 per share. Analysts cite recent clinical updates and ongoing litigation developments as key factors influencing their outlook.

Shared on 19 Sep 25

Fair value Increased 5.20%

Fast Track Immunology Asset Will Debut Amid Execution Risks

Nektar Therapeutics’ consensus price target has increased to $101.17, driven by positive Phase 2b REZOLVE-AD results for rezpegaldesleukin, which demonstrated robust efficacy and safety in atopic dermatitis, supporting increased conviction in its differentiated clinical and commercial profile. Analyst Commentary Bullish analysts are raising price targets following positive Phase 2b REZOLVE-AD data for rezpegaldesleukin, with all primary and secondary endpoints met and robust efficacy and safety demonstrated in moderate-to-severe atopic dermatitis.

Shared on 01 May 25

Fair value Increased 48%

Fast Track Immunology Asset Will Debut Amid Execution Risks

Shared on 24 Apr 25

Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 3.50%

Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 15%

Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects

AnalystConsensusTarget has increased revenue growth from -25.3% to -16.0%, decreased future PE multiple from 149.9x to 100.1x and increased shares outstanding growth rate from 0.0% to 0.0%.